{
    "nct_id": "NCT00411580",
    "title": "A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and A\u00df-specific Antibody Response Following Three Subcutaneous Injections of CAD106",
    "status": "COMPLETED",
    "last_update_time": "2013-03-27",
    "description_brief": "This study will evaluate the safety and tolerability and A\u00df-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.\n\nPatients also had a 2 year follow-up to assess disease progression where no drug was administered.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "CAD106 (active A\u03b2 immunotherapy vaccine; A\u03b21\u20136 peptide conjugated to Q\u03b2 virus\u2011like particle)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The study evaluates safety, tolerability and the A\u03b2-specific antibody response to CAD106, indicating the intervention is an active immunotherapy targeting amyloid\u2011\u03b2 pathology (disease-modifying intent). \ue200cite\ue202turn0search2\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 drug = CAD106, described in the literature as A\u03b21\u20136 peptide coupled to a Q\u03b2 virus\u2011like particle (vaccine) given as subcutaneous injections (three in the core 52\u2011week study) to induce A\u03b2\u2011specific antibodies; primary outcomes are safety/tolerability and immunogenicity (A\u03b2 antibody response). \ue200cite\ue202turn0search4\ue202turn0search3\ue201",
        "Reflect: Classification \u2014 CAD106 is a biologic vaccine that elicits B\u2011cell (antibody) responses against amyloid\u2011\u03b2 and was developed to engage Alzheimer\u2019s pathology rather than act as a symptomatic cognitive enhancer or neuropsychiatric treatment; therefore it fits the 'disease\u2011targeted biologic' category. Evidence of target engagement and immunogenicity is reported in multiple phase 1/2 publications. \ue200cite\ue202turn0search6\ue202turn0search7\ue201",
        "Web search results used (key sources): Phase\u20111 study describing safety and A\u03b2\u2011specific antibody response (Lancet / PubMed). \ue200cite\ue202turn0search2\ue201; Long\u2011term/phase IIa core + extension publication (Alzheimer's Research & Therapy). \ue200cite\ue202turn0search3\ue201; Phase\u20112b randomized study and open access summary (PMC). \ue200cite\ue202turn0search7\ue201; Preclinical description of CAD106 composition and mechanism (A\u03b21\u20136\u2013Q\u03b2 VLP). \ue200cite\ue202turn0search6\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational product CAD106 is an active immunotherapy (vaccine) designed to elicit A\u03b2\u2011specific antibodies against the N\u2011terminus of amyloid\u2011\u03b2 (A\u03b21\u20136) presented on a Q\u03b2 virus\u2011like particle \u2014 indicating the intervention specifically targets amyloid\u2011\u03b2 pathology (disease\u2011modifying, not symptomatic). \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Act: Extracted details from the trial description and publications \u2014 drug = CAD106 (A\u03b21\u20136 peptide conjugated to Q\u03b2 VLP), given as subcutaneous/intramuscular injections in 3 (core) or repeated doses; primary outcomes include safety/tolerability and A\u03b2\u2011specific antibody (immunogenicity) response, and studies report target engagement (A\u03b2 antibody induction and effects on peripheral/plaque measures). \ue200cite\ue202turn0search1\ue202turn0search5\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 CADRO category A) Amyloid beta is the most specific and appropriate match because the vaccine directly targets amyloid\u2011\u03b2 to induce an anti\u2011A\u03b2 immune response. The trial is not multi\u2011target (R) and is therapeutic (not diagnostic), so 'A) Amyloid beta' is correct. Key supporting publications used are listed below. \ue200cite\ue202turn0search1\ue202turn0search5\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results used (key sources):",
        "- Safety, tolerability, and antibody response: first\u2011in\u2011human 52\u2011week randomized study (CAD106) \u2014 PubMed (Lancet / phase 1 abstract). \ue200cite\ue202turn0search1\ue201",
        "- Long\u2011term treatment / phase IIa core + extension \u2014 Alzheimer's Research & Therapy (CAD106 immunogenicity and safety). \ue200cite\ue202turn0search5\ue201",
        "- Phase\u20112b randomized study (immunogenicity results summary). \ue200cite\ue202turn0search0\ue201",
        "- CAD106 effects on amyloid PET in prevention cohort (Generation Study reporting). \ue200cite\ue202turn0search4\ue201",
        "- Review on virus\u2011like particle based A\u03b2 vaccines (mechanism and CAD106 as VLP candidate). \ue200cite\ue202turn0search6\ue201"
    ]
}